Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24917211 | 0.91 | TMPRSS2 (0.39) | TMPRSS2 | |
| SCHEMBL24917128 | 0.88 | TMPRSS2 (0.34) | TMPRSS2 | |
| SCHEMBL25912570 | 0.86 | TMPRSS2 (0.40) | TMPRSS2TSHRCYP1A2HTR1ACYP2D6 | |
| SCHEMBL24791252 | 0.83 | TMPRSS2 (0.53) | TMPRSS2TSHRCYP1A2HTR1ACYP2D6 | |
| SCHEMBL24917219 | 0.81 | TMPRSS2 (0.39) | TMPRSS2LMNA | |
| SCHEMBL24917060 | 0.80 | TMPRSS2 (0.36) | TMPRSS2TSHR | |
| SCHEMBL24916918 | 0.79 | TMPRSS2 (0.35) | TMPRSS2 | |
| SCHEMBL24917328 | 0.79 | TMPRSS2 (0.34) | TMPRSS2 | |
| SCHEMBL25912420 | 0.79 | TMPRSS2 (0.40) | TMPRSS2TSHR | |
| SCHEMBL25912633 | 0.79 | TMPRSS2 (0.38) | TMPRSS2TSHRCYP1A2HTR1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885TSHR 4711/4885CYP1A2 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.